Health Trials

About this trial

The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and whether early diagnosis influences the prognosis in high-risk populations thanks to the possibility of being able to use a more effective treatment. The primary objective is to evaluate 5-year overall survival (OS) in patients with Human Epidermal Growth Factor Receptor 2 positive (HER2+) or high-risk Triple Negative (TN) undergoing surveillance with DWB-MRI.

Eligibility criteria

Qualifiers

Pre or post-menopausal patient with histologically confirmed invasive breast cancer stage II - III HER2 + or TN operated breast carcinoma or patients underwent neoadjuvant treatment (included cT4d) with residual disease at definitive surgery

No evidence of distant metastases at baseline perioperative radiological staging (DWB-MRI, total body Computed Tomography (CT) or Positron Emission Tomography (PET/CT) must be performed +/- 1 month from surgery)

No relevant comorbidities

Eastern Cooperative Oncology Group (ECOG) performance status 0

Disqualifiers

Absolute contraindications that exclude the execution of the MRI investigation, regardless of the clinical indication

Relative contraindications that include situations in which the innocuousness of the examination is not documented with certainty that therefore do not recommend the execution, except for serious indications related to the patient's clinical need

Older age (>75 years)

Previous or concomitant other malignancy except basal or squamous cell carcinoma of the skin or adequately treated in situ carcinoma of the cervix

Trial design

Treatments tested in this trial

  • Diffusion whole body MRI

Treatment groups

145 Participants
are divided into 1 treatment group

Locations

1
European Institute of Oncology20141, Milan Italy

Sponsors and collaborators

European Institute of Oncology

Lead sponsor

Source ClinicalTrials.gov